Table 1.
Baseline characteristics of participants in the Parkinson's disease and control groupsa.
| Characteristics | Parkinson's disease (n = 8) | Controls (n = 8) |
|---|---|---|
| Age (y) | 71.4 ± 2.6 | 71.3 ± 2.4 |
| Male participants, n (%) | 5 (63) | 3 (38) |
| Race/Ethnicity, n (%) | ||
| White | 8 (100) | 7 (88) |
| American Indian or Alaska Native | - | 1 (13) |
| Non-hispanic | 7 (88) | 8 (100) |
| BMI | 26.7 ± 1.4 | 27.7 ± 0.7 |
| Hoehn a Yahr Stage | ||
| 1 | 1 (13) | - |
| 2 | 6 (75) | - |
| 3 | 1 (13) | - |
| PD medications, n (%) | ||
| L-DOPA | 8 (100) | - |
| MAO-B inhibitors | 3 (38) | - |
| MDS-UPDRS scoresb | ||
| Part I | 8.9 ± 3.1 | - |
| Part II | 11.3 ± 2.9 | - |
| Part III | 31.9 ± 5.2 | - |
| Part IV | 2.6 ± 1.3 | - |
| Total score | 54.6 ± 9.9 | - |
| MoCA score | 26.6 ± 1.0 | - |
a
BMI, body mass index; L-DOPA, carbidopa-levodopa; MAO-B, monoamine oxidase B; MDS-UPDRS, Movement Disorder Society Unified Parkinson's Disease Rating Scale; MoCA, Montreal Cognitive Assessment. Values are represented as mean ± standard error of the mean; categorical variables are represented as total counts.
b
Three participants were noted to be in the “OFF” period despite taking their Parkinson's medication.